Meta-Analysis of Clinical Trials

Keith O’Rourke, Beverley Shea and George A. Wells
Additional contact information
Keith O’Rourke: University of Ottawa, Ottawa Hospital
Beverley Shea: University of Ottawa, Ottawa Hospital
George A. Wells: University of Ottawa

Chapter 16 in Applied Statistics in the Pharmaceutical Industry, 2001, pp 397-424 from Springer

Abstract: Abstract Meta-analysis (MA) may loosely be defined as the explicit analysis and summary of multiple investigations or studies. Being such, it offers the potential to reach the goal of keeping up to date in the drug research and development process without sacrificing thoroughness. Theoretically, meta-analysis can effectively summarize the accumulated research on a topic, promote new questions on the matter, as well as channel the stream of clinical research toward relevant horizons. Consequently, meta-analyses can be very important in the drug research and development process—from initial consideration of a new drug through the conduct of Phase III studies to possible removal of a drug.

Keywords: Markov Chain Monte Carlo; Model Check; Individual Study; Random Effect Model; Total Parenteral Nutrition (search for similar items in EconPapers)
Date: 2001
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-1-4757-3466-9_16

Ordering information: This item can be ordered from
http://www.springer.com/9781475734669

DOI: 10.1007/978-1-4757-3466-9_16

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().